Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68